Juries May Have To Decide If Zantac Causes Cancer

There is no doubt that Zantac contains high amounts of NDMA and that NDMA can cause cancer

Monday, March 15, 2021 - When one sorts through the allegations that taking Zantac (ranitidine) regularly for multiple years can lead to cancer, many outstanding questions remain. Zantac may degrade to form N-nitrosodimethylamine (NDMA) in levels that are orders of magnitude greater than the 96 NGS per tablet that the FDA deemed acceptable if the tablets are stored at high temperatures. We also know that NDMA is a dangerous carcinogen used to produce cancer tumors in laboratory test animals. It would figure, therefore, that if high levels of NDMA are in Zantac tablets, and a person ingests those tablets regularly for years or decades, that one could develop cancer but there is no scientific proof of this. All we have to go on is that there is a logical link. Zantac attorneys have vast experience and a winning track record litigating against big corporations and pharmaceutical companies.

Science Times (ST) recently published an article titled: "Does Zantac Have Cancer-Causing Properties," which posed the question. ST quotes a South Korean study that analyzed the risks of ingesting NDMA, "Researchers have found that repeated exposure to a daily dose of NDMA increases the risk of cancer. But, this is not conclusive as other studies have found that NDMA doesn't increase cancer risks." In another study that tried to emulate the effects of NDMA under certain physiological conditions, scientists confirmed that there may be a link. "NDMA levels increase when it is stored at and above room temperature. So scientists at the Memorial Sloan Kettering Cancer Center in New York conducted a study on the digestion of ranitidine. By simulating a stomach with gastric fluid and combining it with various Zantac products, the scientists were able to prove that when ingested, ranitidine does produce high levels of NDMA."

Regardless of the final confirmation or denial of Zantac causing cancer, justice may be served once the findings of a Department of Justice investigation of Zantac's makers are made public. The DOJ thinks that GalaxoSmithKline, the maker of Zantac, and Sanofi that acquired GSK, may have violated the False Claims Act in failing to disclose what the company knew about NDMA in Zantac. The companies may have lied to government investigators about ranitidine degrading into NDMA under certain conditions. The companies also failed to warn the public of such dangers. Thousands of individuals with stomach, bladder, esophagus, and other cancer have registered to file lawsuits against Sanofi and GSK for failing to warn consumers. Reuters wrote: "The U.S. Department of Justice has opened an investigation into whether drugmakers including Sanofi SA failed to disclose to the federal government information about the potential presence of a probable carcinogen in the heartburn drug Zantac." The False Claims Act prohibits companies from submitting false claims to government healthcare programs for payment. In addition to the DOJ allegations against Sanofi and GSK, New Mexico Attorney General Hector Balderas has sued the companies claiming they withheld what they knew about the dangers associated with the drugs from the public.

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.